On October 4, 2024, TD Cowen upgraded CVS Health (NYSE: CVS) to Buy from Hold, raising its price target to $85 from $59. This represents a potential upside of 35%, driven by significant updates to CVS’s Medicare Advantage (MA) business. Analyst Charles Rhyee pointed to the company’s reduction of over-the-counter…
The AMD (NASDAQ: AMD) stock price has crawled back in the past few weeks, rising from the August low…
Energy stocks have done well this week as the rising geopolitical risks in the Middle East pushed crude oil…
John Sheehan, a popular Wells Fargo analyst, has identified a set of companies that he believes will do well…
The Indian equity market remained volatile on Friday on heightened tensions in the Middle East and higher crude oil…
Global oil markets are on edge as Goldman Sachs cautions that crude prices could skyrocket by $20 per barrel…
Nvidia is back in the spotlight as a class action lawsuit over crypto-related misrepresentation gains new momentum. The US…
ChargePoint (CHPT) stock price has imploded this year, falling by over 41% while the S&P 500 and Nasdaq 100…